Journal
EYE
Volume 27, Issue 4, Pages 545-553Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/eye.2012.294
Keywords
glaucoma; adherence; compliance; Travatan Dosing Aid; electronic monitoring
Categories
Funding
- National Institutes of Health Research (NIHR) [PB-PG-1207-14119] Funding Source: National Institutes of Health Research (NIHR)
- Department of Health [PB-PG-1207-14119] Funding Source: Medline
- National Institute for Health Research [PB-PG-1207-14119] Funding Source: researchfish
Ask authors/readers for more resources
Aims and purpose Adherence to long-term treatment regimens for primary open-angle glaucoma holds a challenge for both clinicians and patients. The study aims were to (i) establish the magnitude of travoprost non-adherence using an Electronic Adherence Monitor (EAM), (ii) compare electronic with patient self-reported adherence, and (iii) explore the application of a previously reported method of graphically presenting adherence data to a larger cohort over a longer monitoring period. Methods A cohort study of patients using travoprost for glaucoma or ocular hypertension was conducted. All participants used an EAM and adherence data were collected prospectively for 2 months. Self-reported adherence was obtained using the Morisky Medication Adherence Scale (MMAS); patients also reported frequency of missed doses. Potential predictors of adherence were collected via a structured interview. EAM-recorded interdose intervals were plotted graphically. Results Of 100 patients invited to participate, 98 consented and EAM data were collected successfully from 88 participants. The median EAM adherence score for the cohort was 88.9% (interquartile range: 71.2, 92.2). When dichotomised (>= 80%: adherent; <80%: non-adherent), EAM identified 36.7% as non-adherent and MMAS 12.2%. EAM data were used to classify five types of adherence behaviour including a category representing levels of >= 97% maintained by 21% of participants. Conclusion EAM revealed good adherence to glaucoma monotherapy but poor agreement with patient self-reported adherence. An adherence category of persistent and exceptionally high adherence to travoprost over a 2-month period was identified. Eye (2013) 27, 545-553; doi:10.1038/eye.2012.294; published online 18 January 2013
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available